Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Ascending) Administration Route Package Effective Date Package Discontinuation Date Status
00046-1100-52 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Nov. 11, 2019 In Use
00046-1100-81 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1100-91 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1102-51 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 May 22, 2020 In Use
00046-1102-52 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Feb. 10, 2020 In Use
00046-1102-81 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1102-91 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1104-51 00046-1104 Estrogens, Conjugated Premarin 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 1, 2004 April 30, 2013 In Use
00046-1104-81 00046-1104 Estrogens, Conjugated Premarin 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 1, 2004 In Use
00046-1104-91 00046-1104 Estrogens, Conjugated Premarin 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 1, 2004 In Use
00069-1305-10 00069-1305 epoetin alfa-epbx RETACRIT 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1307-10 00069-1307 epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1308-10 00069-1308 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1309-04 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1309-10 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1306-10 00069-1306 epoetin alfa-epbx RETACRIT 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1318-04 00069-1318 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 1, 2020 In Use
00069-1318-10 00069-1318 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov. 9, 2020 In Use
00078-0180-01 00078-0180 Octreotide Acetate Sandostatin 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0180-61 00078-0180 Octreotide Acetate Sandostatin 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00078-0181-01 00078-0181 Octreotide Acetate Sandostatin 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0181-61 00078-0181 Octreotide Acetate Sandostatin 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00078-0182-01 00078-0182 Octreotide Acetate Sandostatin 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0182-61 00078-0182 Octreotide Acetate Sandostatin 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00310-0720-10 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2010 In Use
00310-0720-25 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2010 Sept. 21, 2010 In Use
00310-0720-50 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular May 20, 2002 Oct. 31, 2015 In Use
00641-6174-01 00641-6174 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6174-10 00641-6174 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
25021-0455-05 25021-0455 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 29, 2020 In Use
57884-2021-01 57884-2021 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 16, 2013 In Use
60429-0910-30 60429-0910 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Sept. 28, 2016 Feb. 28, 2023 No Longer Used
62935-0303-30 62935-0303 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Feb. 26, 2003 In Use
67457-0311-05 67457-0311 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Sept. 9, 2019 In Use
00591-5019-02 00591-5019 Fulvestrant Fulvestrant 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 22, 2019 June 30, 2024 In Use
23155-0170-31 23155-0170 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Aug. 31, 2023 In Use
23155-0687-41 23155-0687 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0688-41 23155-0688 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0689-41 23155-0689 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
00781-9055-12 00781-9055 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular July 1, 2023 In Use
43598-0233-11 43598-0233 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Aug. 21, 2023 In Use
51655-0227-26 51655-0227 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Feb. 15, 2023 In Use
51655-0227-52 51655-0227 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral June 28, 2023 In Use
51655-0860-52 51655-0860 ESTRADIOL ESTRADIOL 0.5 mg/1 Hormonal Therapy Estrogen Oral Feb. 9, 2023 In Use
51655-0860-26 51655-0860 ESTRADIOL ESTRADIOL 0.5 mg/1 Hormonal Therapy Estrogen Oral May 4, 2023 In Use
55150-0394-02 55150-0394 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intravenous June 30, 2023 In Use
68788-8481-01 68788-8481 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral July 13, 2023 In Use
68788-8481-03 68788-8481 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral July 13, 2023 In Use
68788-8481-06 68788-8481 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral July 13, 2023 In Use
68788-8481-09 68788-8481 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral July 13, 2023 In Use

Found 10,000 results in 3 milliseconds — Export these results